Physician profile
Harsh Patel
NPI 1437594892
$2,532.04
in general payments reported to CMS, 2019-2025
34 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $83.32 · 2021: $195 · 2022: $206 · 2023: $85.22 · 2024: $659 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $290.26 | 2019 | |
| Cvrx, INC. | $280.05 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $225.96 | 2019-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $217.04 | 2021-2025 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.43 | 2021-2024 | Trulance |
| Abbott Laboratories | $180.43 | 2024 | Cardiomems |
| Abbvie INC. | $118.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.64 | 2022-2025 | |
| Ardelyx, INC. | $105.82 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $91.11 | 2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $84.20 | 2019-2021 | |
| Esperion Therapeutics, INC. | $63.34 | 2022-2024 | Nexletol |
| Cardiva Medical, INC. | $55.10 | 2024 | Optowire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.22 | 2020-2021 | |
| Abiomed | $40.24 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $34.65 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $31.09 | 2024 | Arcalyst |
| Penumbra, INC. | $30.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.86 | 2021 | |
| Janssen Biotech, INC. | $29.66 | 2024 | Stelara |
| Bridgebio Pharma, INC. | $27.56 | 2025 | Attruby |
| Silk Road Medical, INC. | $27.41 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Regeneron Pharmaceuticals, INC. | $27.06 | 2025 | Evkeeza |
| Braintree Laboratories, INC. | $21.36 | 2024 | Sutab, Suflave |
| Actelion Pharmaceuticals US, INC. | $20.75 | 2025 | Uptravi |
| Convatec INC. | $18.81 | 2024 | |
| Merck Sharp & Dohme LLC | $18.81 | 2021 | |
| Inspire Medical Systems, INC. | $18.00 | 2024 | Inspire |
| Cardiovascular Systems INC. | $17.69 | 2022 | |
| Novo Nordisk INC | $15.21 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.92 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $12.33 | 2021 | |
| Ethicon US, LLC | $6.96 | 2023 | Stratafix, Vistaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.